In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...
Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel ...
Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.
CD137 is a potent immune costimulatory receptor that promotes T-cell activation and enhances antitumor immune responses. However, systemic activation of CD137 can result in excessive immune ...
Contrary to public concerns, receiving frequent COVID-19 booster vaccinations will not weaken the immune system, providing reassurance to vulnerable groups facing new variants. Study: No evidence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results